Diva Laboratories, Ltd.

As of June 30, 2026, Diva Laboratories, Ltd. carries a market capitalization of 1.76B, placing it among publicly traded companies globally. Its enterprise value stands at 1.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Diva Laboratories, Ltd. has 58.67M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Diva Laboratories, Ltd. maintains a current ratio of 2.41, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Diva Laboratories, Ltd. recorded 11.33M in income tax expense.

As of the close on October 22, 2026, Diva Laboratories, Ltd.'s stock has declined approximately 19.11% over the past 52 weeks. The 50-day moving average sits at 32.02, while the 200-day moving average is 32.28.

As of June 30, 2026, Diva Laboratories, Ltd. holds 549.14M in cash and equivalents against 1.61M in total debt, resulting in a net debt position of -549.14M. Total book value stands at 967.23M, with working capital of 703.09M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Diva Laboratories, Ltd.'s most recent stock split took place on October 19, 2020 with a 911:760 split ratio.